GlassScriptPhysician profile
Carmen A Julian
NPI 1447249636
$6,242.43
in general payments reported to CMS, 2019-2025
32 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,572 · 2020: $1,052 · 2021: $378 · 2022: $955 · 2023: $336 · 2024: $513 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.01 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $814.62 | 2020-2025 | |
| Galderma Laboratories, L.P. | $581.62 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $570.05 | 2019-2022 | |
| Pfizer INC. | $469.03 | 2019-2022 | |
| Journey Medical Corporation | $386.50 | 2019-2022 | |
| Almirall LLC | $383.76 | 2019-2020 | |
| Janssen Biotech, INC. | $310.80 | 2020-2025 | Tremfya |
| Lilly USA, LLC | $275.92 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $271.02 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $256.58 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $244.71 | 2019-2022 | |
| Amgen INC. | $227.10 | 2019-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $212.18 | 2019-2022 | |
| Genzyme Corporation | $155.15 | 2020-2025 | |
| Ucb, INC. | $137.06 | 2020-2024 | Bimzelx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $123.31 | 2019-2020 | |
| Stemline Therapeutics INC. | $117.76 | 2019 | |
| Sun Pharmaceutical Industries INC. | $112.81 | 2019-2023 | Odomzo, Blu-U |
| Celgene Corporation | $92.44 | 2019 | |
| Vyne Pharmaceuticals INC. | $68.77 | 2020 | |
| Incyte Corporation | $66.61 | 2022-2023 | Opzelura |
| Sanofi-Aventis U.S. LLC | $57.22 | 2020 | |
| Epi Health, LLC | $52.35 | 2019 | |
| Biofrontera INC. | $49.85 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $43.83 | 2019 | |
| Mylan Pharmaceuticals INC. | $36.51 | 2019 | |
| Encore Dermatology INC. | $35.87 | 2019 | |
| Sandoz INC. | $28.36 | 2019 | |
| Promius Pharma LLC | $24.51 | 2019 | |
| Glenmark Therapeutics INC. | $18.00 | 2019 | |
| Dermira, INC. | $16.57 | 2021 | |
| Organon LLC | $1.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Julian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.